In plain words
In two of the three trials, taking akkermansia did not change the overall mix of bacteria in the gut. One of those trials reported more akkermansia itself in stool, especially with the live form. Another trial found it settled in well in people who started with little of it.
The short answer
Of three randomized trials, two measured the overall makeup of gut bacteria and found no overall change. One tested live or pasteurized akkermansia (2019); the ledger has no n for it. The other gave a heat-killed form to 150 people for 12 weeks (2024). A 2021 paper that appears to describe the 2019 trial reports that 10 billion cells a day for 3 months in 32 people was associated with more akkermansia in stool. The third trial (2025, 12 weeks, the ledger has no n) found high colonization in people starting with low akkermansia. Certainty is low, because the trials used different forms and measures.
Where the evidence sits
No overall change
Depends on starting level
■ measured by the source's own study · ◪ pooled analysis, may overlap studies counted here · □ reported, reviewed or argued, no new data
Who says what
| Source | Finding | Design | People | Dose and length | Funding and independence |
|---|---|---|---|---|---|
| Depommier et al., Nature Medicine, 2019 | Overall structure of the gut microbiome unchanged | Randomized trial, live or pasteurized | Overweight and obese volunteers; n not in ledger | Not in ledger | Not in ledger |
| Depommier et al., Cells, 2021 | Associated with more akkermansia in stool, more with the live form | Randomized trial; appears to describe the 2019 trial | 32 | 10 billion cells a day for 3 months | Not in ledger |
| Lee et al., 2024 | No difference in diversity or composition against placebo | Randomized, placebo-controlled, heat-killed | 150 | One 500 mg capsule a day for 12 weeks | Not in ledger |
| Zhang et al., 2025 | High colonization in people starting low | Randomized trial | Not in ledger | Dose not in ledger; 12 weeks | Not in ledger |
Overall structure of the gut microbiome unchanged
Associated with more akkermansia in stool, more with the live form
No difference in diversity or composition against placebo
High colonization in people starting low
Does akkermansia change the overall mix of gut bacteria?
Researchers at UCLouvain, publishing in Nature Medicine in 2019, gave overweight and obese volunteers live or pasteurized akkermansia. The ledger has no n, dose or duration for this row. On the whole community, they wrote:
the supplementation with either Pasteurized A.muciniphila or Alive A.muciniphila did not affect the overall structure of the gut microbiome
Lee and colleagues (2024) gave 150 people one 500 mg capsule of a heat-killed strain, or a placebo, every day for 12 weeks. They compared stool samples between the groups:
we could not find significant differences in the diversity and composition of human fecal microbiota between the ETB-F01 and placebo groups
The same trial reports no serious adverse events in either group.
Does the bacterium itself build up in the gut?
A 2021 paper in Cells by Depommier and colleagues appears to describe the same trial as the 2019 report. In 32 people taking 10 billion cells a day for 3 months, it looked at akkermansia alone:
both supplementations were associated with a significant increase of the abundance of A. muciniphila recovered in the feces of the participants, with a more pronounced effect for the alive form
Zhang and colleagues (2025) ran a 12-week trial of a strain called AKK-WST01. The ledger has no n or dose for it. They split results by how much akkermansia people carried at the start:
In participants with low baseline A. muciniphila, AKK-WST01 supplementation showed high colonization efficiency
Why the sources disagree
No independent measurements in the ledger contradict each other on this question. The results differ in what was measured. The 2019 and 2024 trials looked at the whole community, while the 2021 paper and the 2025 trial tracked akkermansia itself. The forms differ too: live, pasteurized and heat-killed bacteria were each tested, and the 2021 paper reports a larger rise with the live form. The 2025 trial reports its colonization result for people who started with low levels.
What would settle it
A pre-registered, placebo-controlled trial randomizing adults to live, pasteurized or heat-killed akkermansia at 10 billion cells a day for 12 weeks. It would sequence stool at baseline, 6 weeks, 12 weeks and 4 weeks after stopping, report both overall diversity and akkermansia abundance, and analyze results by starting level. A matching result from a second group would raise certainty.
How this page was made
The 4 sources come from a search of PubMed-indexed studies on akkermansia given as a supplement. Studies were left out when they tested other supplements, used only animals, or enrolled people with liver disease. The ledger holds 5 gut microbiome composition claims from 5 sources; this page uses four of those sources, plus one safety claim. Every claim was copied word for word from its source into the Longevity Circle ledger and checked against the original text, and a person approved each one. Certainty follows the GRADE levels used in medical reviews. Drafting was assisted by AI.
Changelog: 29 Sep 2026, first version, 4 sources.
